Unmet clinical needs in bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3 SUPPL. 1, 2003, Pages

  Sachs, Gary S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DISABILITY; DRUG EFFICACY; FUNCTIONAL DISEASE; HUMAN; MAINTENANCE THERAPY; MANIA; MOOD DISORDER; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SUICIDE; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 0037708864     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200306001-00002     Document Type: Conference Paper

References (43)

1. Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000;61(suppl 9):35-40.
2. Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-Depressive Association (NMDA) survey of bipolar members. J Affect Disorders 1994;31:281-94.
3. Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997;27:1079-89.
4. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness-1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:213-9.
5. Narrow WE, Regier DA, Rae DS, et al. Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Arch Gen Psychiatry 1993;50:95-107.
6. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025-33.
7. Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder: reducing suicide risk with lithium. Ann N Y Acad Sci 2001;932:24-43.
8. Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999;60(Suppl 2):57-62.
9. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999;60(suppl 2):77-84; discussion, 111-6.
10. Judd L, Akiskal H, Schettler P. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;56:530-7.
11. Sachs G. New approaches to bipolar disorder. http://www.med-scape.com/Medscape/psychiatry/TreatmentUpdate/2000/tu05/ pnt-tu05.html. 2000.
12. Maj M. The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence. Bipolar Disord 2000;2:93-101.
13. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12-21.
14. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-24.
15. Gelenberg AJ, Kane JM, Keller MB. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorders. N Engl J Med 1989;321:1489-93.
16. Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: the importance of the previous pattern of course of the illness. Clin Neuropharmacol 1990;13:S66-S70.
17. Swann AC, Bowden CL, Calabrese JR, et al. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr Scand 2000;101:444-51.
18. McElroy SL, Keck PE Jr. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000;48:539-57.
19. Nemeroff CB. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000;61(suppl 13):19-25.
20. Sachs G, Ghaemi SN. Risperidone versus placebo (combined with lithium or valproate) in acute mania [abstract]. Acta Neuropsychiatrica 2000;12:169.
21. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-7.
22. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9.
23. Dunayevich E, Strakowski SM. Quetiapine for treatment-resistant mania. Am J Psychiatry 2000;157:1341.
24. DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Child Adolesc Psychopharmacol 2002;41:1216-23.
25. Vieta E, Gasto C, Colom F, et al. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol 1998;18:172-4.
26. Bauer MS, Kirk GF, Gavin C, et al. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J Affect Disord 2001;65:231-41.
27. Strauss J, Carpenter W. The prediction of outcome in schizophrenia. I. Characteristics of outcome. Arch Gen Psychiatry 1972;27:739-46.
28. Colom F, Vieta E, Martinez-Aran A, et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000;61:549-55.
29. Keck PE, Jr., McElroy SL, Strakowski SM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996;57:292-7.
30. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press, 1990.
31. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153:993-1000.
32. Maj M. Lithium prophylaxis of bipolar disorder in ordinary clinical conditions. In: Goldberg JF, Harrow M, eds. Bipolar Disorders: Clinical Course and Outcome. Washington, DC: American Psychiatric Press, 1999:21-39.
33. Akiskal HS, Walker P, Puzantian VR, et al. Bipolar outcomes in the course of depressive illness: phenomologic, familial, and pharmacologic predictors. J Affect Disord 1983;5:115-28.
34. Weissman MM, Prusoff BA, Merikangas KR. Is delusional depression related to bipolar disorder? Am J Psychiatry 1984;141:892-93.
35. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry 2000;48:558-72.
36. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152:1130-38.
37. Tohen M, Vieta E, Ketter T, et al. Olanzapine and olanzapine-fluoxetine combination (OFC) in the treatment of bipolar depression. In: Proceedings of the 23rd Congress of the Collegium International Neuro-Psychopharmacologicum. June 23-27, Montreal, Canada, 2002.
38. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88.
39. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9.
40. Bowden CL, Calabrese JR, McElroy SL, et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999;45:953-8.
41. Walden J, Schaerer L, Schloesser S, et al. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Disord 2000;2:336-9.
42. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000;61:638-42.
43. Ghaemi SN, Sachs GS. Long-term risperidone treatment in bipolar disorder: 6-month follow up. Int Clin Psychopharmacol 1997;12:333-8.